{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-24-000075","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.489087+00:00","generated_at":"2026-05-30T01:44:01.560170+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SI-BONE reports Q3 revenue $40.3M (+19% YoY); expects positive Adjusted EBITDA in Q4","bullets":["Worldwide revenue $40.3M (+19% YoY); U.S. revenue $38.3M (+18% YoY).","Net loss improved 34% to $6.6M; Adjusted EBITDA loss narrowed 94% to $0.2M.","Over 1,200 active U.S. physicians (+15%); commercialized iFuse TORQ TNT for pelvic fractures.","Updated FY2024 revenue guidance to $165-166M (prev $165-167M); expects Adj EBITDA positive in Q4.","Refinanced $36M term loan, lowered borrowing cost, extended maturity to 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-24-000075","json":"https://secwatch.observer/filing/0001459839-24-000075.json","markdown":"https://secwatch.observer/filing/0001459839-24-000075.md","text":"https://secwatch.observer/filing/0001459839-24-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983924000075/0001459839-24-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983924000075/sibn-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:44:01.560170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}